Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIII

New England Journal of Medicine

Volumn 318, Issue 15, 1988, Pages 947-950

  Nilsson, Inga Marie ^a   Berntorp, Erik ^a   Zettervall, Olle ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN;

CLINICAL ARTICLE; HEMOPHILIA A; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0023933922     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198804143181503     Document Type: Article

References (17)

1. Nilsson IM. Haemorrhagic and thrombotic diseases. London: John Wiley, 1974:87.
2. Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1975; 1: 336–85.
3. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19–29.
4. Allain J-P, Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 1976; 47: 973–82.
5. Nilsson IM, Sundqvist SB, Freiburghaus C. Extracorporeal protein A–sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res 1984; 150: 225–41.
6. Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 9169–73.
7. Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods. Thromb Haemost 1979; 42: 1230–9.
8. Holmberg L, Borge L, Ljung R, Nilsson IM. Measurement of antihaemophilic factor A antigen (VIII: CAg) with a solid phase immunoradiometric method based on homologous non-haemophilic antibodies. Scand I Haematol 1979; 23: 17–24.
9. Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand I Haematol 1976; 16: 369–82.
10. Kasper CK, Aledort L, Aronson D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612. abstract.
11. Allain JP, Verroust F, Soulier JP. In vitro and in vivo characterization of factor VIII preparations. Vox Sang 1980; 38: 68–80.
12. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765–8.
13. Seifried E, Gaedicke G, Pindur G, Rasche H. The treatment of haemophilia A inhibitor with high dose intravenous immunoglobulin. Blut 1984; 48: 397–401.
14. Nilsson IM, Sundqvist S-B, Ljung R, Holmberg L, Frieburghaus C, Björlin G. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Scand J Haematol 1983; 30: 458–64.
15. Brackmann H-H. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181–5.
16. Rizza CR. The management of haemophiliacs who have antibodies to factor VIII. Scand J Haematol [Suppl] 1984; 40: 187–93.
17. van Leeuwen EF, Mauser-Bunschoten EP, van Dijken PJ, Kok AL, Sjamsoedin-Visser EJM, Sixma JJ. Disappearance of factor VIII: C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291–7.